Albumin Market Report 2026

The albumin market size has grown strongly in recent years. It will grow from $7.16 billion in 2025 to $7.81 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to limited availability of plasma-derived albumin, growing prevalence of liver diseases and burns, increasing use in diagnostic kits, rising biopharmaceutical R&D activities, early adoption in laboratory and research applications.

The albumin market size is expected to see strong growth in the next few years. It will grow to $10.62 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to advancement in recombinant albumin technology, growing demand for personalized medicine, expansion of albumin in drug delivery systems, increasing biopharmaceutical manufacturing, rising investment in therapeutic and cosmetic applications. Major trends in the forecast period include rising demand for human serum albumin in therapeutics, growing use of albumin in drug formulations and vaccines, expansion of recombinant albumin applications in biopharma, increasing adoption of albumin in cell culture and diagnostic kits, focus on albumin-based research and personalized medicine.

The increasing incidence of diabetes is expected to drive the growth of the albumin market in the coming years. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels, which over time can lead to renal complications such as diabetic nephropathy. A major factor contributing to the rising incidence of diabetes is increasing obesity rates, as extensive epidemiological evidence shows a strong correlation between higher body mass index and a significantly elevated risk of diabetes. Albumin supports patient management by assisting in monitoring kidney function and guiding treatment interventions in individuals with diabetes. For instance, in April 2025, the International Diabetes Federation (IDF), a Belgium-based nonprofit organization, reported that diabetes affected an estimated 589 million adults and 9.5 million people with type 1 diabetes in 2024, including 1.9 million children and adolescents, with the total number of individuals living with the disease projected to reach 853 million by 2050. Therefore, the rising incidence of diabetes is fueling growth in the albumin market.

Major companies operating in the albumin market are developing innovative products, such as animal- and human-origin-free recombinant albumin, to better serve customers with advanced features. Animal- and human-origin-free recombinant albumin is a type of albumin manufactured using a non-mammalian expression system, such as yeast, and does not contain any components derived from animals or humans. For instance, in March 2023, Albumedix, a UK-based manufacturer of recombinant human albumin (rHA), partnered with Heartseed Inc., a Japan-based clinical-stage biotech company, to launch Recombin, a critical excipient for the production of Heartseed's investigational cell therapy, HS-001, as it enters its first-in-human clinical trial. This collaboration represents a key milestone in the development of HS-001, which has the potential to transform the treatment of multiple diseases. Incorporating Recombin into the manufacturing process ensures optimal performance and stability of the cell therapy, enhancing its therapeutic potential.

In November 2025, Evonik Industries AG, a Germany-based specialty chemicals company, partnered with InVitria to expand global access to animal-component-free recombinant human serum albumin (rHSA) for biopharmaceutical and advanced therapy applications. Through this partnership, Evonik aims to strengthen its portfolio in biologics, cell therapies, and formulation technologies by integrating InVitria’s high-purity recombinant albumin into its offerings. InVitria is a U.S.-based biotechnology company that produces animal-free recombinant proteins, including recombinant albumin used in vaccines, cell culture, and therapeutic development.

Major companies operating in the albumin market are Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, Baxter International Inc., CSL Limited, Grifols SA, Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Kedrion S.p.A., Biotest AG, Jiangxi Boya Bio-Pharmaceutical Co. Ltd., BPL (Bio Products Laboratory), Kamada Ltd., Proliant Biologicals, SeraCare Life Sciences Inc., HiMedia Laboratories, Albumedix Ltd., Medxbio Pte Ltd., Ventria Bioscience Inc., China Biologic Products Holdings Inc.

North America was the largest region in the albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the albumin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the albumin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the albumin market by increasing costs of imported plasma-derived and recombinant proteins, as well as processing equipment. Segments such as human serum albumin for therapeutic use and recombinant albumin for biopharmaceutical formulation are most impacted, with north america, europe, and asia-pacific regions facing procurement challenges. This has led to higher production costs and slower adoption in some therapeutic and research applications. Positively, tariffs are encouraging local production, investment in recombinant technologies, and regional self-reliance in albumin manufacturing.

The albumin market research report is one of a series of new reports that provides albumin market statistics, including albumin industry global market size, regional shares, competitors with a albumin market share, detailed albumin market segments, market trends and opportunities, and any further data you may need to thrive in the albumin industry. This albumin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Albumin is a type of protein present in blood plasma, serum, muscle, egg whites, milk, and other animal products, as well as in many plant tissues and fluids. It is a simple, water-soluble, and heat-coagulable protein that plays a vital role in maintaining fluid balance and transporting hormones, vitamins, and enzymes throughout the body.

The main types of albumin include human serum albumin, bovine serum albumin, and recombinant serum albumin. Human serum albumin is a protein found in blood plasma that helps maintain osmotic pressure and transports various substances, including hormones and fatty acids. Its applications include therapeutics, drug formulation, vaccines, components of media, and more, distributed through sales channels such as business-to-customer (B2C) and business-to-business (B2B). The end users include hospitals and clinics, pharmaceutical and biotechnology companies, and research institutes.

The albumin market consists of sales of egg albumin, plant-based albumin, and recombinant human albumin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.